There is a gene called **dystrophin** — the largest gene in the human genome — and when it has the wrong mutations, boys born with it face a life defined by progressive muscle loss.
**Duchenne muscular dystrophy (DMD)** is one of the most devastating genetic conditions known to medicine. Caused by mutations in the dystrophin gene on the X chromosome, it affects approximately **1 in 3,500 to 5,000 male births** worldwide. The muscles of the body — including the heart and the diaphragm — progressively weaken and degenerate. Most boys with DMD lose the ability to walk before their teens. Most require ventilatory support by early adulthood. Life expectancy, even with the best modern supportive care, is typically in the third or fourth decade.
There is no cure. The treatments that exist manage symptoms — they do not address the underlying genetic cause.
On **March 9, 2026**, that picture became a little less bleak.
**The FDA Fast Track Designation**
The **U.S. Food and Drug Administration** granted **Fast Track designation** to **PBGENE-DMD**, an investigational gene editing therapy developed by **Precision BioSciences**, a North Carolina-based biotech company.
Fast Track is an FDA programme designed to accelerate the development and review of treatments for serious conditions where there is an unmet medical need. It provides:
📋 **More frequent collaboration** with FDA during development 🔬 **Rolling review** — allowing FDA to evaluate completed sections as they're submitted ⏱️ **Potential for expedited approval** if clinical data is strong
**What PBGENE-DMD Does**
PBGENE-DMD uses Precision BioSciences' proprietary **ARCUS® genome editing platform** for *in vivo* gene editing — delivered into the patient's body, editing the patient's own DNA directly in the tissues that need it.
The target is the **exon 45–55 hotspot** — a stretch of DNA where mutations are concentrated in DMD patients, accounting for disease in up to **60% of all boys with DMD**.
The ARCUS system works through **gene excision**: removing the exons where mutations concentrate. This deletion restores the **reading frame** of the dystrophin gene, allowing the patient's cells to produce a **near full-length, functional dystrophin protein**.
The protein produced is shorter than fully healthy dystrophin — but functional. Patients who naturally carry a similar deletion (Becker muscular dystrophy) typically have much milder disease and longer lives. The goal of PBGENE-DMD is to convert the molecular consequences of Duchenne into something more like Becker.
**Strong Preclinical Data**
Preclinical studies in humanised DMD mouse models showed:
💪 **Significant dystrophin restoration** across multiple muscle types, including cardiac and skeletal muscles 🫁 **Durable results** — edited cells continue producing dystrophin over time ⚡ **Functional improvement** in muscle strength in mouse models 🎯 **High specificity** — ARCUS edits the intended target without significant off-target effects
**The FUNCTION-DMD Trial**
Precision BioSciences plans to initiate the **Phase 1/2 FUNCTION-DMD clinical study** — the first human testing of PBGENE-DMD. The company held a virtual investor event on March 17, 2026 to present clinical plans.
Initial data from multiple patients is expected by end of 2026.
**The Bigger Picture**
The DMD field is moving faster than at any point in history. A condition considered medically untreatable beyond symptoms as recently as ten years ago now has multiple approved therapies, active regulatory programmes, and a growing gene therapy pipeline.
For the boys with mutations in exons 45–55 — and for their parents — watching the fastest genomic medicine programme in history converge on their specific condition is not an abstraction. It is, cautiously, hope. 🧬💙
*Sources: Precision BioSciences (investor.precisionbiosciences.com, March 9, 2026) · BioSpace · CRISPR Medicine News · Nasdaq · FDA.gov · CRISPR Medicine News Weekly (March 13, 2026)*
